Your browser doesn't support javascript.
loading
The Biodistribution of the Spike Protein after Ad26.COV2.S Vaccination Is Unlikely to Play a Role in Vaccine-Induced Immune Thrombotic Thrombocytopenia.
Marquez-Martinez, Sonia; Khan, Selina; Lubbe, Joan van der; Solforosi, Laura; Costes, Lea M M; Choi, Ying; Boedhoe, Satish; Verslegers, Mieke; Heerden, Marjolein van; Roosen, Wendy; Jonghe, Sandra De; Kristyanto, Hendy; Rezelj, Veronica; Hendriks, Jenny; Serroyen, Jan; Tolboom, Jeroen; Wegmann, Frank; Zahn, Roland C.
Afiliación
  • Marquez-Martinez S; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Khan S; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Lubbe JV; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Solforosi L; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Costes LMM; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Choi Y; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Boedhoe S; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Verslegers M; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Heerden MV; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Roosen W; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Jonghe S; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Kristyanto H; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Rezelj V; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Hendriks J; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Serroyen J; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Tolboom J; Janssen Research & Development (JRD), B-2340 Beerse, Belgium.
  • Wegmann F; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
  • Zahn RC; Janssen Vaccines & Prevention (JVP), 2333 CN Leiden, The Netherlands.
Vaccines (Basel) ; 12(5)2024 May 20.
Article en En | MEDLINE | ID: mdl-38793810
ABSTRACT
Ad26.COV2.S vaccination can lead to vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but severe adverse effect, characterized by thrombocytopenia and thrombosis. The mechanism of VITT induction is unclear and likely multifactorial, potentially including the activation of platelets and endothelial cells mediated by the vaccine-encoded spike protein (S protein). Here, we investigated the biodistribution of the S protein after Ad26.COV2.S dosing in three animal models and in human serum samples. The S protein was transiently present in draining lymph nodes of rabbits after Ad26.COV2.S dosing. The S protein was detected in the serum in all species from 1 day to 21 days after vaccination with Ad26.COV2.S, but it was not detected in platelets, the endothelium lining the blood vessels, or other organs. The S protein S1 and S2 subunits were detected at different ratios and magnitudes after Ad26.COV2.S or COVID-19 mRNA vaccine immunization. However, the S1/S2 ratio did not depend on the Ad26 platform, but on mutation of the furin cleavage site, suggesting that the S1/S2 ratio is not VITT related. Overall, our data suggest that the S-protein biodistribution and kinetics after Ad26.COV2.S dosing are likely not main contributors to the development of VITT, but other S-protein-specific parameters require further investigation.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Vaccines (Basel) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos